FDA Reviews Rules on Banned Proteins in Cow Feed Safety
Published Date: 6/27/2025
Notice
Summary
The FDA wants your thoughts on keeping records about animal proteins that can’t be used in cow feed to keep animals safe and healthy. This affects farmers, feed makers, and anyone involved in animal food, with no new costs but a chance to improve rules. You’ve got 60 days to share your ideas before the FDA decides what’s next!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Recordkeeping for Banned Ruminant Proteins
The FDA is asking for public comment for 60 days on recordkeeping rules about animal proteins that are prohibited in cow (ruminant) feed. This request specifically affects farmers, feed makers, and anyone involved in animal food; the notice says there are no new costs now but offers a chance to improve the rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-11955, Agency Information Collection Activities; Proposed Collection; Comment Request; Tobacco Health Document Submission
The FDA wants your thoughts on how they collect info about tobacco health documents. If you’re a tobacco company or health expert, this could affect how you submit important papers. They’re asking for comments over the next 60 days—no big costs, just a chance to help shape the rules!
Next: 2025-11957, Agency Information Collection Activity: Notice to Department of Veterans Affairs of Veteran or Beneficiary Incarcerated in Penal Institution
The VA wants your thoughts on how they collect info when a veteran or beneficiary goes to jail. This helps keep benefits fair and accurate. They’re asking for comments over the next 60 days—no cost changes, just smoother info sharing!